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ESCC: esophageal squamous cell carcinoma
HUVEC:human umbilical vein endothelial cell
IPCL: intra-papillary capillary loop
MAPK: mitogen-activated protein kinase
MVD: microvascular density
Nrp1: neuropilin1
PDGF: platelet-derived growth factor
Q-PCR: quantitative polymerase chain reaction 
VEGF: vascular endothelial growth factor
































































Early stage of esophageal squamous cell carcinoma (ESCC) is known to be accompanied by 
angiogenesis and morphological changes of microvessels. Transcription factor Sox2 is amplified in 
various cancers including ESCC, but the role of Sox2 in the carcinogenesis and angiogenesis has not 
been determined. Hence, we aimed to investigate the role of Sox2 in the early stage of ESCC. We found 
that the expression of Sox2 was significantly higher in early stage ESCC tissues than that in their adjacent 
normal tissues. We then established Sox2-inducible normal human esophageal squamous cell line 
(HetSox2) to investigate the role of Sox2 in esophageal carcinogenesis and angiogenesis in vitro. Sox2 
overexpression led to increased cell proliferation and spheroid formation. The culture supernatant of 
Sox2-overexpressing HetSox2 induced migration and sprouting of endothelial cell line HUVEC. As for 
the mechanism, we found that the expression of secreted protein Suprabasin was directly induced by 
Sox2. Suprabasin enhanced proliferation of normal human esophageal squamous cells and HUVEC 
when added to the culture. Moreover, Suprabasin enhanced migration and sprouting of HUVEC cells, 
which were observed with the culture supernatant of Sox2-oversxpressing HetSox2. This angiogenic 
effect of Suprabasin was abolished by inhibiting AKT phosphorylation, which suggested its dependence 
on AKT signaling. Finally, we showed that Suprabasin expression and the density of microvessels were 
significantly higher in ESCC tissues with high Sox2 expression. Our study suggested that increased Sox2 
expression in esophageal squamous cells induced Suprabasin expression, and as a result initiated the 































































carcinogenesis via increased cell proliferation and angiogenesis.
































































Esophageal cancer is the sixth leading cause of cancer death partly due to its difficulty of diagnosis 
in its early stage (1). Squamous cell carcinoma, which is common in Eastern Asia, and adenocarcinoma 
are the two major subtypes of esophageal cancer (2,3). In recent years, endoscopic submucosal dissection 
(ESD) or endoscopic mucosal resection (EMR) has become the major treatment for early esophageal 
cancers since the frequency of lymph node metastasis is very limited in their early stage (4). However, 
recognizing the cancerous lesions and sorting out endoscopically resectable lesions by normal white-
light endoscopy could be challenging. Therefore, narrow-band imaging (NBI) endoscopy and iodine-
staining endoscopy are commonly used for detecting esophageal cancers at their early stages (5,6). NBI 
is the optical digital method frequently used to detect cancerous lesions by emphasizing the images of 
microvessels. As for esophageal squamous cell carcinoma (ESCC), magnifying observation under NBI 
endoscopy allows us to observe the morphological changes of intra-papillary capillary loop vessels, 
which help us detect the presence of ESCC and predict their depth of infiltration (7,8). These 
morphological changes of microvessels suggest that some angiogenic factors are playing a role in the 
early stage of ESCC.
Recent genomic comprehensive analyses of advanced ESCC have revealed that there are genomic 
mutations and/or amplifications of p53, Notch1, Ccnd1, Pik3ca, and Sox2 (9-11). Sox2 is one of the four 
transcription factors crucial for producing induced pluripotent stem (iPS) cells (12). Sox2 also 































































contributes to the development of organs such as brain, lung, and stomach (13). In terms of esophagus, 
Sox2 contributes to its development from the foregut, and to the maintenance of its stratified squamous 
epithelium (14). On the other hand, recent studies revealed the involvement of Sox2 in carcinogenesis in 
various organs. Although the suppressed expression of Sox2 is considered to lead to carcinogenesis in 
gastric cancer (15), enhanced Sox2 expression is found in various cancers such as advanced ESCC 
(16,17), cutaneous squamous cell carcinoma (18), lung squamous cell carcinoma (16), and breast cancer 
(19). A previous study reported that Sox2 promoted cell proliferation through AKT/mTORC1 signaling 
in ESCC (20), and another study reported that Sox2 overexpression was associated with poor prognosis 
in advanced ESCC patients (21). In addition, Yokota et al reported that suppression of Sox2, using zinc 
finger-based artificial transcription factor, inhibited tumor growth in ESCC cell lines (22).
Angiogenesis is an essential process in carcinogenesis and ESCC is no exception (23). Angiogenic 
factors such as vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and 
interleukin-8 play a crucial role in the process of endothelial cell proliferation, migration, and vascular 
formation and cause angiogenesis (24-27). Angiogenic factors are known to induce angiogenesis via 
activation of mitogen-activated protein kinase (MAPK) signaling and/or AKT signaling (28,29). The 
correlation between these angiogenic factors and clinical prognosis in advanced ESCC has been reported 
previously (30,31).
Hence, we aimed to investigate the role of Sox2 in carcinogenesis and angiogenesis in early stage ESCC.
































































Patients' information and tissue samples
Forty-seven specimens of early stage ESCC were obtained from patients who underwent ESD at 
Tohoku University Hospital (Sendai, Japan) between March 2014 - October 2017. Clinicopathological 
information on the samples is summarized in Supplementary Table 1. This study was conducted under 
the approval of the Ethical Committee Tohoku University Graduate School of Medicine and examined 
after obtaining informed consent.
Cell culture
Human normal esophageal squamous cell line Het-1A was obtained from American Type Culture 
Collection (ATCC, Manassas, VA) where the cell lines are authenticated by short tandem repeat (STR) 
profiling. Human umbilical vein endothelial cell HUVEC, human embryonic kidney cell HEK293, 
human ESCC cell lines KYSE30, KYSE70, KYSE180, and KYSE450 (32), were purchased from 
Health Science Research Resources Bank (Osaka, Japan) where the cell lines are authenticated by STR 
profiling. Het-1A was cultured in Airway Epithelial Cell Basal Medium (Promo Cell, Heiderburg, 
Germany) supplemented with Growth Medium Supplement Pack (Promo Cell), 4% Tet system 
approved fetal bovine serum (FBS) (Clontech, Mountain View, CA). HUVEC was cultured in F-12K 
medium (Invitrogen life technologies, Carlsbad, CA) supplemented with 10% FBS. HEK293 cells were 































































cultured in DMEM medium (Invitrogen) supplemented with 10% FBS. The other cell lines were 
cultured in F-12 medium and RPMI1640 (Invitrogen) mixed medium supplemented with 2% FBS. All 
cell lines were incubated at 37 °C in a 5% CO2 atmosphere. Cell lines were carefully checked for 
morphologic consistency by microscope.
Establishment of Doxycycline-inducible Sox2 overexpressing Het-1A cells (HetSox2)
 As Sox2 is a gene composed of one exon without intron, we obtained the coding region of Sox2 by 
PCR using the genome extracted from Het-1A cells as a template with the primer pair 
5’-GGGAATTCATGTACAACATGATGGAGACGGAGCTG-3’ and 
5’-GGGGGATCCTCACATGTGTGAGAGGGGCAGTGTGC-3’. After confirming the sequence of 
the acquired PCR product, Sox2 coding region was cloned into pTetOne-Vector (Clontech), so that Sox2 
could be induced by Doxycycline (Dox). We named the constructed vector pTetOneSox2. Het-1A cells 
were transfected with pTetOneSox2 and linear puromycin marker (Clonech), using X-fect Transfection 
Reagent (Clontech). Twenty-four hours after the transfection, the cells were selected by puromycin 
(1µg/ml) (Sigma-Aldrich, St. Louis, MO). The induction of Sox2 expression in the obtained stable clone 
(HetSox2) treated with Dox was confirmed by Western blot. 
Total RNA isolation and quantitative PCR































































Total RNA was isolated with TRIzol reagent (Invitrogen) according to the manufacturer’s protocol. 
After removing the contaminating DNA by DNase (Invitrogen) from the isolated RNA, cDNA was 
synthesized using SuperScript III Reverse Transcriptase (Invitrogen). The synthesized cDNA was 
subjected to quantitative PCR (Q-PCR) using StepOnePlus Real-Time PCR systems (Applied 
Biosystems, Foster City, CA). Primer sets for Sox2, VEGF, PDGF, Neuropilin1 (Nrp1), Notch1, and 
Suprabasin were purchased from Applied Biosystems. Relative expression was calculated by ∆∆CT 
method using StepOneSoftware Version 2.2 (Applied Biosystems).
Western blot
Western blot was performed according to the standard method described previously (33) with the 
following primary antibodies: anti-Sox2 (#3579, Cell Signaling Technology, Danvers, MA), anti-
Suprabasin (#sc-515037, Santa Cruz Biotechnology, Dallas, TX), anti-AKT (#9272, Cell Signaling 
Technology), anti-phospho-AKT (#4060, Cell Signaling Technology), anti-p38 (#8690, Cell Signaling 
Technology), anti-phospho-p38 (#4511, Cell Signaling Technology), anti-p44/42 (#4695, Cell Signaling 
Technology), anti-phospho-p44/42 (#4370, Cell Signaling Technology), anti-JNK (#9258, Cell 
Signaling Technology), anti-phopho-JNK (#4668, Cell Signaling Technology), anti-β-actin (#sc-1616R, 
Santa Cruz Biotechnology). The membranes were then incubated with appropriate secondary antibody 
for an hour. Protein bands were detected with ECL prime reagent (GE Healthcare, Little Chalfont, 































































Buckinghamshire, UK) and were visualized using a lumino-image analyzer (VersaDoc5000; Bio-Rad, 
Hercules, CA). 
Immunohistochemistry
Tissue samples were fixed in 10% buffered formaldehyde and embedded in paraffin. Serial 
sections cut from paraffin blocks (3µm) were dewaxed. After inhibiting the endogenous peroxidase 
activity, antigen retrieval was carried out by autoclaving the sections in 10mmol/l citrate buffer. For 
primary antibodies, we applied anti-Sox2 1:100 (#14962, Cell Signaling Technology), anti-CD34 1:100 
(#M7165, Dako Cytomation, Carpintera, CA), and anti-Suprabasin 1:100 (#sc-515037, Santa Cruz 
Biotechnology), and incubated sections overnight at 4 °C. After the application of appropriate secondary 
antibodies for 30 minutes at room temperature, bindings were visualized with Liquid DAB+ Substrate 
Chromogen System (Dako). Sections were counterstained with haematoxylin in the standard fashion. 
The expression of Sox2 was evaluated by TissueFAXS (TissueGnostics, Vienna, Austria). Sox2 
positive cells were defined as cells whose nuclei were positive for Sox2. Sox2 positive rate in ESCC 
tissues were compared with that of their adjacent normal tissues. Sox2 positive rate in ESCC tissues was 
defined as "high" when it was greater than the average, while Sox2 positive rate in ESCC tissues was 
defined as "low" when it was below the average. Microvessels in ESCC tissues were counted in 5 areas 
at 200 folds magnification on the basis of CD34 staining. Microvascular density (MVD) was indicated 































































according to the international consensus (34). Immunostaining of Suprabasin in ESCC tissues was 
evaluated in a double-blinded manner by two independent observers using a semiquantitative reactivity 
scoring system for both staining intensity (0: negative, 1: weak, 2: moderate, 3: intense) and staining 
percentage of positively stained cancer cells (0: none, 1: 1-10%, 2: 11-50%, 3: 51-80%, 4: >80%). The 
final immunohistochemistry (IHC) scores ranged from 0 to 12 as previously reported (35).
 
Cell proliferation Assay
Cells were seeded on 96-well plates (7.0×103 cells/well) and were cultured for 3 days with or 
without Dox. Twenty µl of 3-(4,5-dimethylthiazol-2-yl)-5-(3-carcoxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium, inner salt (MTS) was added to the culture and the plate was incubated for 
another 4 hours at 37℃. Then, the absorbance at 490nm was measured in each well to evaluate cell 
proliferation. The average absorbance of 8 wells was compared. Suprabasin recombinant protein 
(OriGene, Rockville, MD) was added to the culture at the final concentration of 5ng/ml in the indicated 
experiments.
Spheroid Assay
Cells were embedded in Type I collagen gels (Cellmatrix Type I-A; Nitta Gelatin, Osaka, Japan) 
(3.0×104 cells/well) on 24-well plates to form spheroids. Spheroids were cultured in the culture 































































supernatant of HetSox2 treated with or without Dox for 6 days. The number of spheroids was calculated 
by ImageJ (National Institutes of Health, Bethesda, MD) after staining with 0.1% crystal violet. Average 
number of total spheroids in randomly selected three fields per well was calculated.
Migration Assay
HUVEC cell migration was investigated using 24-well plates and 8µm PET membrane (Corning). 
Culture supernatant of HetSox2 was added to the lower chamber as a chemoattractant. HUVECs were 
seeded on the upper chamber (5.0×104 cells/chamber), and plates were incubated for 4 hours at 37 ℃. 
Cells were then fixed with 4% paraformaldehyde and stained with 0.1% crystal violet. Unmigrated cells 
were removed with cotton bud. Number of migrated HUVECs was calculated using BZ-9000 
(KEYENCE, Osaka, Japan). Average number of migrated HUVECs in randomly selected three fields 
per insert was calculated.
Sprouting Assay
HUVECs were seeded on a 96-well Ultra-low attachment plate (Corning) (2.0×103 cells/well) and 
incubated for 16 hours at 37 ℃ to form macrosphere. HUVEC macrosphere was embedded in Type I 
collagen gels (Nitta Gelatin), applied to 24-well plate, and incubated for 24 hours at 37 ℃ in the culture 
supernatant of Dox treated or untreated HetSox2 to form sprouts. HUVEC macrospheres were fixed 































































with 4% paraformaldehyde and sprout length was measured by ImageJ (National Institutes of Health). 
Average cumulative length of sprouts in three macrospheres was calculated.
Immunofluorescence
Dox treated or untreated HetSox2 cells were fixed with 4% paraformaldehyde and permeabilized 
with 0.5% Triton-X in PBS. Cells were incubated overnight at 4˚C with anti-Suprabasin antibody (#sc-
515037, Santa Cruz Biotechnology). After being incubating with Alexa Fluor 555-labeled anti-mouse 
IgG secondary antibody (#A28180, Invitrogen), the cells were then incubated with Alexa Fluor 488-
labeled anti-Sox2 antibody (#53-9811-82, eBioscience, San Diego, CA) for 3 hours at room temperature. 
Nuclei were counterstained with 4',6'-diamidino-2-phenylindole (DAPI)(Invitrogen). Images were 
captured using a laser scanning confocal microscope (Nikon C2si; Tokyo, Japan).
Luciferase Assay
Transcriptional factor-binding site in the 5'-promoter region of human Suprabasin was analyzed 
using JAPAR (http://jaspar.genereg.net). Then, the 5'-promoter region of Suprabasin was obtained by 
PCR and ligated into Luciferase Reporter Vector-pGL3 (Promega, Madison, WI) using DNA Ligation 
Kit (Takara Bio, Shiga, Japan). The constructed luciferase vector, pTetOneSox2 and pRL-TK vector 
(Promega) were transfected into HEK293 cells using TransIT-X2 transfection reagent (Mirus Bio, 































































Madison, WI). The transfected cells were cultured for 48 hours in the presence or the absence of Dox, 
and then were lysed with Passive Lysis Buffer (Promega). The luciferase activity was measured using 
Dual-Luciferase Reporter Assay System (Promega).
Chromatin immunoprecipitation Assay
Chromatin immunoprecipitation (ChIP) was performed for Dox-treated and untreated HetSox2 
with anti-Sox2 antibody (#2748, Cell Signaling Technology) using ChIP-IT Express (Active motif, 
Carlsbad, CA) following manufacturer's protocol. Briefly, HetSox2 cells were cultured with or without 
Dox for 3 days. Cells were then fixed with 1% formaldehyde (Sigma-Aldrich) and chromatin was 
extracted from their nuclei. Immunoprecipitation using either anti-Sox2 antibody or normal rabbit IgG 
(#2729, Cell Signaling Technology) was performed and the immunoprecipitated chromatin was 
subjected to PCR using PrimeStar GXL (Takara Bio) with Primers 5’-
TTTGGGTGGAGTCAAGTGTCCAGG-3’ and 5’-TTGGTGCCAAGGGGAGAGACTGAG-3’. 
The obtained PCR products were electrophoresed on a 0.9% agarose gel containing Tris-acetate EDTA 
buffer and ethidium bromide. 
Statistical Analysis
All experiments were performed three to five times. Student’s t-test was performed to evaluate the 































































significance of the differences between two groups using Microsoft Excel 2016. A value of p<0.05 was 
considered as statistically significant. Results are indicated as means ± standard deviation.
































































Immunohistochemistry of Sox2 in early stage ESCC
We investigated the expression of Sox2 by immunohistochemistry (IHC) in early stage ESCC 
obtained by endoscopic resection. Forty-seven ESCC samples consisted of 37 mucosal cancers and 10 
submucosal cancers. In the adjacent normal squamous epithelial tissue, Sox2 immunoreactivity was 
observed in the nuclei of cells in the basal layer, but the immunoactivity decreased toward the princkle 
layer and granular layer (Figure 1A). In the mucosal cancer tissues, Sox2 immunoreactivity showed 
stronger staining than the adjacent normal squamous tissue, especially in the basal layer. In the 
submucosal cancer tissues, Sox2 was diffusely stained almost throughout the layer, mainly in the 
infiltrating lesions (Figure 1A). Quantitative image analysis using TissueFAXS showed that Sox2-
positive rate in cancer tissues (64.7%) was significantly higher than that in adjacent normal tissues 
(53.0%) (Figure 1B).
Enhanced cell proliferation and tumorigenicity by Sox2 induction
To investigate the role of Sox2 in esophageal carcinogenesis, we established Dox-inducible Sox2 
overexpressing Het-1A cells (HetSox2, see Materials and methods). After confirming that Sox2 was 
overexpressed in Dox-treated HetSox2 (Figure 2A), we performed MTS assay to evaluate whether cell 
proliferation was enhanced by Sox2 overexpression in these cells. Dox-treated HetSox2 showed 































































increased proliferation compared to Dox-untreated HetSox2 (Figure 2B). Next, we performed spheroid 
assay to evaluate the effect of Sox2 on tumorigenicity. Total spheroid area of Dox-treated HetSox2 was 
significantly larger than that of Dox-untreated HetSox2 (Figure 2C). These results suggested that 
overexpression of Sox2 in normal esophageal squamous cells induced cell proliferation and 
tumorigenicity.
HUVEC migration and sprouting by the induction of Sox2 
Since early stage ESCC is known to be accompanied by transformation of microvessels (7), we 
next investigated the influence of Sox2 overexpression on angiogenesis. To this end, we employed 
HUVEC and performed migration assay and sprouting assay. In migration assay, the culture supernatant 
of Dox-treated HetSox2 induced HUVEC migration to a greater degree compared to that of Dox-
untreated HetSox2 (Figure 2D). In sprouting assay, the culture supernatant of Dox-treated HetSox2 
formed significantly more sprouts compared to that of Dox-untreated HetSox2 (Figure 2E). These results 
suggested that some kind of growth factors related to proliferation, angiogenesis, and differentiation were 
secreted from Sox2 overexpressing HetSox2, and that they were involved in the migration of endothelial 
cells and the formation of new vascular structures.
Identification of Suprabasin as a growth factor secreted from Sox2 overexpressing HetSox2  































































To identify the growth factors related to angiogenesis and differentiation induced by Sox2 
overexpressing HetSox2, we extracted the RNA of Dox-treated and untreated HetSox2 and performed 
Q-PCR for the candidate genes. Unexpectedly, VEGF, the major angiogenic factor previously reported 
to be expressed in advanced ESCC (30,31), was not upregulated in Dox-treated HetSox2 (Figure 3A). 
In addition, PDGF and Nrp1, which are also factors related to angiogenesis, and Notch1, which is a 
factor related to differentiation, were not induced by Sox2 (Figure 3A). On the other hand, we found that 
Suprabasin expression was induced to 2.58 ± 0.27folds by Sox2 induction (Figure 3A). This induction 
of Suprabasin by Sox2 was confirmed by immunofluorescence study, which showed that Dox-treated 
HetSox2 cells expressed nuclear Sox2 and cytoplasmic Suprabasin, while these expressions were limited 
in Dox-untreated HetSox2 cells (Figure 3B). Similarily, Suprabasin was expressed in Sox2-expressing 
ESCC cell lines, whereas its expression was scarce in Sox2-deficient Het-1A cells (Figure 3C). These 
findings suggested that Sox2 induced Suprabasin. Since Suprabasin is a secreted protein specifically 
expressed in stratified squamous epithelium and is known to be involved in the differentiation of 
keratinocytes (36,37), we decided to focus on this molecule .
We then investigated the molecular mechanism involved in Suprabasin induction by Sox2. 
Examination of the promoter region of Suprabasin by JASPAR predicted a probable binding site of 
Sox2 in the position -1566/-1559 (Figure 3D). Hence, we hypothesized that Sox2 directly regulated 
Suprabasin expression, and constructed a luciferase reporter vector containing this binding site to verify 































































this hypothesis (Figure 3D, see Materials and methods). We found that overexpression of Sox2 led to 
increased luciferase activity (6.36 ± 0.92folds, Figure 3E). In addition, ChIP assay revealed that Sox2 
bound to this binding site located in the promoter region of Suprabasin (Figure 3F). These results 
suggested that Sox2 bound to the position -1566/-1559 of Suprabasin promoter region, and that it 
directly induced Suprabasin expression.
The effect of Suprabasin on cell proliferation and angiogenesis
We then investigated whether Suprabasin had an effect on cell proliferation by MTS assay. We 
found that Het-1A cells cultured in the presence of Suprabasin (5ng/ml) showed increased proliferation 
compared to the cells cultured in the absence of Suprabasin (Figure 4A). This result suggested that 
Suprabasin induced cell proliferation of esophageal squamous cells.
Since the supernatant of Sox2-overexpressing HetSox2 induced the migration and sprouting of 
HUVEC (Figure 2D and E), we evaluated the angiogenic effect of Suprabasin by HUVEC migration 
assay and sprouting assay. In migration assay, Suprabasin induced migration of HUVEC to a greater 
degree (Figure 4B). Furthermore, in sprouting assay, Suprabasin induced significantly longer sprout 
elongation (Figure 4C). These results suggested that Suprabasin had an angiogenic effect.
AKT signaling is involved in the angiogenic effect of Suprabasin































































Since a previous report showed that Suprabasin activated AKT signaling (38), and since AKT 
signaling and MAPK signaling are the major pathways downstream of VEGF (28,29), we examined 
whether these signaling pathways were involved in angiogenesis. First of all, we investigated whether 
Suprabasin activated AKT and MAPK signaling by Western blot and found that AKT phosphorylation 
and p38 phosphorylation were enhanced by the addition of Suprabasin (Figure 5A, upper and middle 
panel). On the other hand, phosphorylation of p42/44 did not differ by the addition of Suprabasin (Figure 
5A, lower panel).
LY294002 is a known inhibitor of AKT signaling (39). After confirming that AKT 
phosphorylation could be inhibited by LY294002 (10μM), we investigated whether AKT signaling is 
involved in angiogenesis. We found that LY294002 (10μM) significantly inhibited the migration of 
HUVEC (Figure 5B). On the other hand, p38 MAPK inhibitor SB202190 (10μM) had no influence on 
HUVEC migration (Figure 5C). These results suggested that Suprabasin acted as an angiogenic factor 
via AKT signaling. 
Sox2, Suprabasin, and CD34 expression in early stage ESCC. 
We then evaluated the expression of Sox2, Suprabasin, and endothelial cell marker CD34 in human 
early stage ESCC tissues by immunohistochemistry. We observed that Sox2 was diffusely stained in the 
nuclei of ESCC cells and that Suprabasin was highly expressed in the cytoplasm of these cells compared 































































to the adjacent normal squamous cells (Figure 6A). In addition, the number of CD34-positive 
microvessels was greater in the Sox2 and Suprabasin expressing ESCC tissues (Figure 6A). Next, we 
evaluated the expression of Suprabasin and the density of CD34-positive microvessels by a 
semiquantitative immunohistochemical scoring to examine their correlation with Sox2 expression in 
ESCC cases. We found that the expression of Suprabasin (Figure 6B) and the density of CD34-positive 
microvessels (Figure 6C) were significantly higher in early stage ESCC cases with high Sox2 expression. 
These results suggested that Suprabasin was induced in Sox2-overexpressing ESCC cells, and as a result, 
caused angiogenesis in this region.
































































The morphological changes of microvessels have become one of the major characteristics 
important for detecting the existence and speculating the depth of invasion of early stage ESCC, but the 
molecular mechanism underlying these changes have not been determined. In this study, we attempted 
to elucidate the molecular mechanism involved in the carcinogenesis and angiogenesis of early stage 
ESCC from the perspective of Sox2, the transcription factor required for the development and 
maintenance of the esophagus. We found that the expression of Sox2 was enhanced even in early stage 
ESCC, as was reported with advanced ESCC (9). This suggested that Sox2 could be playing a pivotal 
role in the carcinogenesis of ESCC. By using Sox2-overexpressing esophageal squamous cell line 
HetSox2 and endothelial cell line HUVEC, we showed that Sox2 overexpression led to enhanced cell 
proliferation and tumorigenicity as well as accelerated angiogenesis. Furthermore, we identified 
Suprabasin as a direct target of Sox2 and found that Suprabasin induced cell proliferation and 
angiogenesis. Finally, we showed that Sox2-overexpressing ESCC tissues also expressed Suprabasin 
and that the density of microvessels was high in ESCC tissues with high Sox2 expression.
A recent comprehensive molecular analysis of advanced ESCC reported that Sox2 copy number 
is increased in around half of the advanced ESCC (9). Another report showed that Sox2 was genetically 
amplified in ESCC and that cases with Sox2 amplification overexpressed Sox2 (16). In cutaneous 
squamous cell carcinomas, aberrant Sox2 expression was reported to directly regulate the key genes 































































involved in cancer-cell proliferation and stemness (18). Similarly, Sox2 overexpression was reported to 
induce cancer cell proliferation and anti-apoptotic protein expression in head and neck cancers, which is 
another squamous cell carcinoma (40). These reports suggested that Sox2 plays an important role in 
cancer initiation in various squamous cell carcinoma. In the present study, we also showed that early 
stage ESCC tissues exhibited Sox2 expression at a higher degree compared to their adjacent normal 
tissues. In addition, Sox2 overexpression in normal human esophageal squamous cell line significantly 
enhanced proliferation and spheroid formation. These results suggested that abnormally enhanced Sox2 
expression could lead to carcinogenesis, though it is an essential transcription factor for the maintenance 
of the esophagus (14). 
Early stage ESCC is usually accompanied by angiogenesis and morphological changes of 
microvessels, but the molecular mechanism underlying this phenomenon has not been determined. In 
the present study, the culture supernatant of Sox2-overexpressing HetSox2 induced migration and 
sprouting of endothelial cell line HUVEC. This suggested the enhancing effect of Sox2 overexpression 
on angiogenesis. There has been very limited reports about the influence of Sox2 on angiogenesis. 
Among these few reports, Kautzman et al reported that Sox2 deletion in retinal astrocytes led to delayed 
angiogenesis (41). On the other hand, Siegle et al reported that overexpression of Sox2 induced the 
expression of angiogenic factors such as VEGF, Nrp1, and Epiregulin in cutaneous squamous cell 
carcinoma (42). These two reports are in accordance with our result in that Sox2 induced angiogenesis.































































Previously, angiogenic factor VEGF was reported to be overexpressed in advanced ESCC (30,31), 
but we were not able to detect its enhanced expression in our Sox2-overexpressing HetSox2. Instead, we 
identified Suprabasin as a factor induced by Sox2-overexpression. 
Suprabasin was identified by Park et al as a gene involved in the differentiation of cutaneous stem 
cells (36). It is a secreted protein which is expressed in stratified epithelium of skin and esophagus (37). 
To date, there are only two previous reports regarding the regulation of Suprabasin: one showed that it 
was induced by 12-O-tetradecanoylphorbol-13-acetate treatment (36) and the other showed its induction 
by interferon-γ (43). In the present study, we firstly showed that Sox2 induced the activation of 
Suprabasin promoter, which contained a Sox2 binding site, by luciferase assay. Moreover, we showed 
that Sox2 bound to its binding site located in the position -1566/-1559 in Suprabasin promoter by ChIP 
assay. Our findings suggested that Suprabasin was directly induced by Sox2 in the esophagus. 
Aberrant Suprabasin expression has been reported in non-small cell lung cancer (44), salivary 
adenoid cystic carcinoma (45), and advanced ESCC (46). In the present study, Suprabasin induced cell 
proliferation of Het-1A. Moreover, it induced cell migration and sprouting of HUVEC, indicating that 
Suprabasin has an angiogenic effect. According to a previous report, VEGF is not expressed in the early 
phase of ESCC (7), which lets us suspect that Suprabasin but not VEGF is inducing angiogenesis in the 
early stage of ESCC. 
Regarding the signal transduction pathway downstream of Suprabasin, Alam et al reported that 































































knocking down Suprabasin in mouse tumor endothelial cells led to reduced AKT activation (38). In the 
present study, Suprabasin induced phosphorylation of AKT and p38, the typical signal transducers 
downstream of VEGF signaling (28,29). Since we found that inhibiting AKT but not p38 led to reduced 
migration of HUVEC, we assume that AKT signaling is playing a pivotal role in Suprabasin induced 
angiogenesis, but further studies are warranted.
Finally, immunohistochemical analysis revealed that Suprabasin expression and microvessel 
density were higher in early stage ESCC cases with high Sox2 expression, which supported our findings 
obtained from in vitro studies.
In conclusion, we found that Sox2 was overexpressed in early stage ESCC and that Sox2 directly 
induced Suprabasin expression, which led to enhanced cell proliferation in esophageal squamous cells, 
as well as cell migration and sprout formation in endothelial cells. This Sox2-Suprabasin pathway could 
be one of the pathways involved in the carcinogenesis and the angiogenesis of early stage ESCC.
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Figure 1. Sox2 was expressed in early stage ESCC tissues. (A) Hematoxylin-eosin staining and 
immunohistochemistry for Sox2 of mucosal and submucosal ESCC tissues, and their adjacent normal 
tissues are shown. bar: 100μm. (B) Quantification of Sox2 positive rates of cancer tissues and adjacent 
normal tissues are shown. n=47. *p<0.05
Figure 2. Sox2 promoted cell proliferation, spheroid formation, migration, and sprouting.
(A) Dox-induced Sox2 expression of the established HetSox2 was confirmed by Western blot. (B and 
C) MTS assay (B) and spheroid assay (C) were performed with Dox-treated and untreated HetSox2. 
n=5. (C: x40) (D and E) Migration assay (D) and sprouting assay (E) of HUVEC cells were performed 
with the culture supernatant of Dox-treated and untreated HetSox2. n=5. (D: x10, E:x100) *p<0.05
Figure 3. Sox2 directly induced Suprabasin. (A) The expressions of genes related to angiogenesis and 
differentiation in Dox-treated and untreated HetSox2 were evaluated by Q-PCR. n=5. (B) The 
expressions of Sox2 and Suprabasin were assessed by immunofluorescence. Sox2: green, Suprabasin: 
red, DAPI: blue. (C) Expressions of Sox2, Suprabasin, and β-actin of Het-1A and ESCC cell lines were 
evaluated by Western blot. (D) The scheme showing the putative Sox2 binding site in the position -
1566/-1559 of Suprabasin promoter and the luciferase construct containing this region. TSS; 































































transcription starting site. (E) Suprabasin promoter activity in Dox-treated and untreated HetSox2 was 
assessed by luciferase assay. n=5. (F) ChIP assay was performed for the Sox2 binding site in Suprabasin 
promoter using anti-Sox2 antibody. Rabbit IgG was used as an isotype control. *p<0.05
Figure 4. Suprabasin promoted cell proliferation and angiogenesis. (A) Suprabasin was added to 
the culture of Het-1A and MTS assay was performed. n=3. (B) HUVEC migration assay was performed 
with Suprabasin added to the culture medium of the lower chamber. n=3. (x10) (C) Suprabasin was 
added to the culture of HUVEC and sprout formation was evaluated. n=3. (x100) *p<0.05
Figure 5. AKT signaling was involved in Suprabasin induced angiogenesis. (A) Suprabasin was 
added to the culture of HUVEC. Cell lysates were collected at the indicated time points and were 
subjected to Western blot analyses to evaluate AKT, p38, and ERK activation. (B) HUVEC migration 
assay was performed with LY294002 added to the lower chamber together with Suprabasin. n=3. (x10) 
(C) HUVEC migration assay was performed with SB202190 added to the lower chamber together with 
Suprabasin. n=3. (x100) N.S.; not statistically significant. *p<0.05
Figure 6. Sox2, Suprabasin, and CD34 were expressed in the identical region of early stage ESCC. 
(A) Representative immunohistochemical images for Sox2, Suprabasin, and CD34 in early stage ESCC 































































tissues and their adjacent normal tissues. bar: 100μm. (B and C) Comparison of Sox2 expression and 
Suprabasin expression (B) or CD34-positive microvascular density (C) in ESCC tissues. n=47. *p<0.05






























































































































































































































































































































































































Supplementary Table 1. Clinicopathological characteristics of ESCC patient samples
Characteristics Number of cases (%)
Gender
Male      33 (70.2)
Female      14 (29.8)
Age 
≧65 　   33 (70.2)
＜65      14 (29.8)
T classification
 T1      47 (100.0)
 T2       0 (0.0)
 T3       0 (0.0)
 T4       0 (0.0)
N classification
 N0      47 (100.0)
 N1       0 (0.0)
 N2       0 (0.0)
 N3       0 (0.0)                                         
M classification
 M0      47 (100.0)
 M1       0 (0.0)
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